Trial Profile
Efavirenz +/- rifampicin +/- isoniazid in volunteers with CYP2B6 516 GG TT polymorphisms
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2013
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Isoniazid/rifampicin; Rifampicin
- Indications HIV infections; Tuberculosis
- Focus Pharmacogenomic; Pharmacokinetics
- 11 Apr 2013 New trial record
- 06 Mar 2013 Results presented at the 20th Conference on Retroviruses and Opportunistic Infections.